<p>Drug firm AstraZeneca India on Tuesday said it has received marketing authorisation for an asthma drug from the Drugs Controller General of India (DCGI).</p>.<p>The company has received approval from the DCGI for Fasenra (Benralizumab solution for injection in a single dose prefilled syringe30 mg/ml) for patients with severe asthma (eosinophilic asthma), AstraZeneca India said in a statement.</p>.<p>Benralizumab (Fasenra) is indicated as an add-on treatment for severe asthma with an eosinophilic phenotype in adult patients, it added.</p>.<p>“The drug firm has always been at the forefront of innovative solutions for non-communicable diseases. Despite currently available therapies, a significant unmet need for effective management of severe Asthma continues to exist globally as well as in India," AstraZeneca India Managing Director Gagandeep Singh Bedi said.</p>.<p>The regulatory approval of Fasenra in India will provide better medicine for the management of eosinophilic asthma and support patients to attain a better quality of life, he added. </p>
<p>Drug firm AstraZeneca India on Tuesday said it has received marketing authorisation for an asthma drug from the Drugs Controller General of India (DCGI).</p>.<p>The company has received approval from the DCGI for Fasenra (Benralizumab solution for injection in a single dose prefilled syringe30 mg/ml) for patients with severe asthma (eosinophilic asthma), AstraZeneca India said in a statement.</p>.<p>Benralizumab (Fasenra) is indicated as an add-on treatment for severe asthma with an eosinophilic phenotype in adult patients, it added.</p>.<p>“The drug firm has always been at the forefront of innovative solutions for non-communicable diseases. Despite currently available therapies, a significant unmet need for effective management of severe Asthma continues to exist globally as well as in India," AstraZeneca India Managing Director Gagandeep Singh Bedi said.</p>.<p>The regulatory approval of Fasenra in India will provide better medicine for the management of eosinophilic asthma and support patients to attain a better quality of life, he added. </p>